JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction ...
InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody Jena, Germany, January 28th 2016 - InflaRx, a ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
A recent study posted to the bioRxiv* preprint server investigated the role of complement component 5a (C5a) and its receptor (C5a receptor type 1, C5aR1) in the pathophysiology of coronavirus disease ...
It is known that dendritic cells and innate lymphoid cells type 2 (ILC2) play key roles in allergen sensitization, and humoral factors such as complement C3a and complement C5a are highly involved in ...
The FDA’s Arthritis Advisory Committee panelists groped through cloudy data while complaining about the design of the phase III trial for Chemocentryx Inc.’s avacopan, and after going overtime ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results